# A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study

Source: https://onco.cc/trials/nct03768063/  
OnCo record `nct03768063` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing Emactuzumab, active and no longer recruiting.

## Summary

A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study is a phase 3 interventional study registered as NCT03768063, led by Hoffmann-La Roche, and active but no longer recruiting on the registry. Official title: An Open Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella B). Planned enrolment is 1000 participants (estimated). The study started in 2019-02-28 and primary completion is expected in 2028-07-05. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-11
- Also known as: IMbrella B
- Tags: ctgov-ingest
- Registry id: NCT03768063
- Phase: 3
- Setting: An Open Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella B)
- Sponsor: Hoffmann-La Roche
- Enrolled: 1000

## Sources

- ClinicalTrials.gov NCT03768063: https://clinicaltrials.gov/study/NCT03768063

## Connected records

- drugs: [Emactuzumab](https://onco.cc/drugs/emactuzumab/)
- companies: [Roche / Genentech](https://onco.cc/companies/roche-genentech/)

---
JSON: https://onco.cc/api/v1/entities/nct03768063.json